Working Experience
2004 ~   Professor and PhD supervisor, Clinical Pharmacology, China Medical University and Professor, Division of Respiratory disease, The First Affiliated Hospital, China Medical University.
1994-~2004, Professor and Head, Clinical Pharmacology, China Medical University
1990~1994 Visiting Scientist at Wellcome Research Laboratories, Becknem, London, UK
1986~1987 Visiting Scholar at Cardiovascular and Pulmonary Research Center and Webb Warring Lung Institute, Health Sciences Center, University of Colorado, USA
1980~1993 Assistant professor, Associate Professor, Professor (PhD supervisor) at Pharmacology
1968~1980 physician at county hospital.

Teach Experiment
Teach Clinical Pharmacology for 10 years, pharmaceutical administration 5 years.

Academic Honor & Awards
Chairman, Clinical Pharmacological Center, China Medical University (1994~2004)
Member of New Drug Evaluation Center, National drug surveillance and administration bureau, China (1994~  )
Member, Ethic Supervision Board for Clinical Trials, China Medical University (2004~  )
National Outstanding Professor issued by Ministry of Education of China (2007)
Deputy Chairman of Pharmaceutical Care Academic Society, Chinese Pharmacological Society (2007~  )
Standing committee member, Cardiovascular Pharmacological Society, Chinese Pharmacological Society (2007~  )
Member of Advisory Board, 《Journal Pharmaceutical Research》(2000~2005, 2005~  )
Member in Editorial Board 《Acta Pharmacologica Sinica》(2000~2005, 2005~  )
Chairman on Serotonin Symposium, The 15th World Congress in Pharmacology, Beijing. (2006)

Publications (Major Teaching Materials)

1.  Wang Huai-liang (Editor in Chief): 《Clinical Pharmacology》 (for Medical Students，People’s Health Publishing House  1990, Beijing

2.  Wang Huai-liang (Editor in Chief): 《Clinical Pharmacology》for Clinical Pharmacy Students, Programing Teaching Material issued by Ministry of Public Health, People’s Health Publishing House 2006, Beijing

3.  Wang Huai-liang (Editor in Chief): 《Clinical Pharmacology》(for Medical and Pharmaceutical Students, Programing Teaching Material issued by Ministry of Education) High Education Publishing House 2009, Beijing

4.  Wang Huai-liang (Deputy Editor in Chief): Pharmacology (for 8 year system Medical Students, Programing Teaching Material issued by Ministry of Public Health) People's Health Publishing House 2005, Beijing

Publications (Major Monograph)

1.  Zhai FG, Zhang XH, Wang HL. Fluoxetine Protects Against Monocrotaline-Induced Pulmonary Arterial Hypertension Is Relevant To Induction Of Apoptosis And Up-Regulation Of Kv1.5 Channels In Rats. Clin Exp Pharmacol Physiol. 2009 Mar 2.

2.  Li XQ, Hong Y, Zhang XH, Wang HL*.  Sertraline protects against monocrotaline induced pulmonary hypertension in rats. Clinical and Experimental Pharmacology and Physiology. 2006; 33: 1047-51.

3.  Song D, Wang HL*, Wang S, Zhang XH.  5-Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells are extracellular signal-regulated kinase pathway dependent. Acta Pharmacologica Sinica 2005; 26(5): 563-567.

4.  Wang HL. Serotonin receptor and transporter as a potential therapeutic target for pulmonary hypertension. Current Opinion Investigating Drugs. 2004; 5(9): 963-966 (Special invitation).

5.  Wang HL. Serotonin receptor as a potential therapeutic target for pulmonary vascular remodeling. Drug Development Research. 2003: 58: 69-73.

6.  Wang HL, Zhang, XH, Chang, TH Effects of tetrandrine on smooth muscle contraction induced by mediators in pulmonary hypertension. Acta Pharmacologica Sinica. 2002; 23(12): 1114-20.

7.  Wang HL, Kilfeather SA, Martin GR, Page CP Effects of tetrandrine on growth factor-induced DNA synthesis and proliferative response of rat pulmonary artery smooth muscle cells. J Pulmonary Pharmacology and Therapeutics. 2000; 13(2): 53-60.

8.  Wang HL, Kilfeather SA, Martin GR, Page CP. Effects of heparin on growth factor-induced monogenesis and proliferative responses of rat pulmonary smooth muscle cells. Acta Pharmacologica Sinica. 1997; 18(5): 397-400.

9.  Wang HL, Zhang XH.  Tetrandrine inhibited chronic “inflammatory” pulmonary hypertension in rats. Acta Pharmacologica Sinica. 1997; 18(5): 401-404.

10. Wang HL, Zhang XH.  Tetrandrine prevents monocrotaline induced pulmonary hypertension in rats. Drug Development Research. 1996; 39(2): 158-160.

11. Dong X, Wang G, Wang HL, Zhang XH, Zong ZH, Xing J. Changes of pulmonary artery protein kinase C activity in rats with chronic inflammatory pulmonary hypertension Nan Fang Yi Ke Da Xue Xue Bao. 2007 Jun; 27(6): 875-7.

12. Liu XJ, Ruan CM, Gong XF, Li XZ, Wang HL, Wang MW, Yin JQ.  Antagonism of transforming growth factor-Beta signaling inhibits fibrosis-related genes. Biotechnol Lett. 2005 Oct; 27(20): 1609-15.

13. Fu XC, Wang MW, Li SP, Zhang Y, Wang HL. Vasodilatation produced by orientin and its mechanism study. Biol Pharm Bull. 2005 Jan; 28(1): 37-41.

14. Wang Yun, Zhang Xin-hua, Wang HL*.  Pharmacodynamic study of adenosine on cardiac ischemic-reperfusion injury in the rabbit. J China Medical University 2007.